Skip Navigation

Annals of Oncology 2008 19(4):603; doi:10.1093/annonc/mdn065
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

in this issue

In this issue

The first 10% of the full text of this article appears below.


   Proliferation identifies high-risk patients amongst small, low-grade breast cancers
 
Approximately 20–30% of patients with lymph-node negative breast cancers die from recurrent disease. Relative survival improvement of 15–20% at 10 years resulting from adjuvant systemic therapy can be expected, but with this level of improvement, the survival benefits and side effects of adjuvant systemic therapy must be considered simultaneously. Consequently, there is a need for accurate and reliable prognostic markers to help identify high-risk patients. Patients with rapidly proliferating tumors, . . . [Full Text of this Article]


   Clinical impact of mutations in GISTs
 

   Prognostic factors for hematotoxicity of chemotherapy in aggressive NHL
 

   Compassionate use of bevacizumab in children and young adults
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?